Relationship of CYP2D6 genetic polymorphisms and the pharmacokinetics of tramadol in Chinese volunteers

Journal of Clinical Pharmacy and Therapeutics

Volumn 35, Issue 2, 2010, Pages 239-247

  Li, Q ^a,b   Wang, R ^b   Guo, Y ^b   Wen, S ^c   Xu, L ^c   Wang, S ^c  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

CYP2D6; DNA microarray; Genetic polymorphisms; Pharmacogenomics; Tramadol

Indexed keywords

CYTOCHROME P450 2D6; DNA; O NORTRAMADOL; OLIGONUCLEOTIDE; TRAMADOL;

ADULT; ARTICLE; CHINESE; DNA MICROARRAY; DNA SEQUENCE; FEMALE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MALE; NORMAL HUMAN; PHARMACOGENOMICS; PLASMA; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; URINALYSIS; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; ANALGESICS, OPIOID; CHINA; CYTOCHROME P-450 CYP2D6; FEMALE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; TRAMADOL;

EID: 77749336151     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2009.01102.x     Document Type: Article

References (30)

1. Mizutani T (2003) PM frequencies of major CYPs in Asians and Caucasians. Drug Metabolism Reviews, 35, 99 106.
2. Persad AS, Stedeford T, Tanaka S, Chen L, Banasik M (2003) Parkinson's disease and CYP2D6 polymorphism in Asian populations: a meta-analysis. Neuroepidemiology, 22, 357 361.
3. Kitada M (2003) Genetic polymorphism of cytochrome P450 enzymes in Asian populations: focus on CYP2D6. International Journal of Clinical Pharmacology Research, 23, 31 35.
4. Benny KA, Adithan C (2001) Genetic polymorphism of CYP2D6. Indian Journal of Pharmacology, 33, 147 169.
5. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M (1994) Genetic analysis of the Chinese cytochrome P450 2D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Molecular Pharmacology, 48, 452 459.
6. Lee CR, McTavish D, Sorkim EM (1993) Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs, 46, 313 340.
7. Slanar O, Nobilis M, Kvetina J, Idle JR, Perlik F (2006) CYP2D6 polymorphism, tramadol pharmacokinetics and papillary response. European Journal of Clinical Pharmacology, 62, 75 76.
8. Abdel-Rahman SM, Leeder JS, Wilson JT, Gaedigk A, Gotschall RR, Medve R (2002) Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation. Journal of Clinical Pharmacology, 42, 24 29.
9. Pedersen RS, Damkier P, Brosen K (2005) Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study. Clinical Pharmacology and Therapeutics, 77, 458 467.
10. Frank D, Jaehde U, Fuhr U (2007) Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. European Journal of Clinical Pharmacology, 63, 321 333.
11. Li Q, Wang R, Xu L, Wen S, Wang S (2006) Genetic polymorphism of cytochrome P450 2D6 in Chinese population detected by gene chips. Chinese Journal of Clinical Rehabilitation, 10, 39 41.
12. Chou WH, Yan FX, Robbins-Weilert DK et al. (2003) Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clinical Chemistry, 49, 542 551.
13. Li Q, Wang R (2006) Simultaneous analysis of tramadol, metoprolol and their metabolites in human plasma and urine by high performance liquid chromatography. Chinese Medical Journal, 119, 2013 2017.
14. Kenneth AB (2002) Genotyping and phenotyping the cytochrome P450 Enzymes. American Journal of Therapeutics, 9, 309 316.
15. Kleiber J, Walter T, Haberhausen G, Tsang S, Babiel R, Rosenstraus M (2000) Performance characteristics of a quantitative, homogeneous TaqMan RT-PCR test for HCV RNA. The Journal of Molecular Diagnostics, 2, 158 166.
16. Huber M, Mundlein A, Dornstauder E, Schneeberger C, Tempfer CB, Mueller MW, Schmidt WM (2002) Accessing single nucleotide polymorphisms in genomic DNA by direct multiplex polymerase chain reaction amplification on oligonucleotide microarrays. Analytical Biochemistry, 303, 25 33.
17. Ji L, Pan SX (2002) Genetic polymorphism of CYP2D6 in Chinese mailand. Chinese Medical Journal, 115, 1780 1784.
18. Ismail R, Teh LK, Amir J, Alwi Z, Lopez CG (2003) Genetic polymorphism of CYP2D6 in Chinese subjects in Malaysia. Journal of Clinical Pharmacy and Therapeutics, 28, 279 284.
19. Cai WM, Chen B, Zhang WX (2007) Frequency of CYP2D6*10 and *14 alleles and their influence on the metabolic activity of CYP2D6 in a healthy Chinese population. Clinical Pharmacology and Therapeutics, 81, 95 98.
20. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proceedings of the National Academy of Sciences of the United States of America, 90, 11825 11829.
21. Marcucci KA, Pearce RE, Crespi C, Steimel DT, Leeder JS, Gaedigk A (2002) Characterization of cytochrome P450 2D6·1 (CYP2D6·1), CYP2D6·2, and CYP2D6·17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine. Drug Metabolism and Disposition, 30, 595 601.
22. Sakuyama K, Sasaki T, Ujiie S, Obata K, Mizugaki M, Ishikawa M, Hiratsuka M (2008) Functional characterization of 17 CYP2D6 allelic variants (CYP2D6·2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57). Drug Metabolism and Disposition, 36, 2460 2467.
23. Fukuda T, Nishida Y, Imaoka S, Hiroi T, Naohara M, Funae Y, Azuma J (2000) The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6. Archives of Biochemistry and Biophysics, 380, 303 308.
24. Hanioka N, Okumura Y, Saito Y et al. (2006) Catalytic roles of CYP2D6·10 and CYP2D6·36 enzymes in mexiletine metabolism: in vitro functional analysis of recombinant proteins expressed in Saccharomyces cerevisiae. Biochemical Pharmacology, 71, 1386 1395.
25. Shen H, He MM, Liu H, Wrighton SA, Wang L, Guo B, Li C (2007) Comparative Metabolic Capabilities and Inhibitory Profiles of CYP2D6·1, CYP2D6·10, and CYP2D6·17. Drug Metabolism and Disposition, 35, 1292 1300.
26. Taguchi M, Nozawa T, Kameyama T, Inoue H, Takesono C, Mizukami A, Hashimoto Y (2003) Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients. European Journal of Clinical Pharmacology, 59, 385 388.
27. Rau T, Heide R, Bergmann K, Wuttke H, Werner U, Feifel N, Eschenhagen T (2002) Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics, 12, 465 472.
28. Murphy GM Jr., Pollock BG, Krishner MA, Pascoe N, Cheuk W, Mulsant BH, Reynolds CF III. (2001) CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression. Neuropsychopharmacology, 25, 737 743.
29. Goetz MP, Knox SK, Suman VJ et al. (2007) The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Research and Treatment, 101, 113 121.
30. Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J (2007) Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. Journal of Clinical Oncology, 25, 3837 3845.